Source: CureToday articles
The first patient has been enrolled in the ARID II trial evaluating Voro Urologic Scaffold to improve continence after prostate cancer surgery.
Recent Content
- RSV and Aging: Understanding Increased Vulnerability
- FDA Approves Penpulimab-Kcqz for Indications in Nonkeratinizing Nasopharyngeal Carcinoma
- For Colon Cancer That No Longer Responds to Treatment, A New Drug Combination Offers Hope
- The Fearless Patient Advocate
- Working to Address Unmet Medical Needs in MPNs
- First Patient Enrolled in ARID II Trial for Prostate Cancer Treatment
- Taking Charge of My Care and Advocacy Following a Cancer Diagnosis
- Sacituzumab Govitecan-hziy Plus Pembrolizumab Improves PFS in Patients With Metastatic Triple-Negative Breast Cancer
- From Workflow Integration to Patient Outcomes: The Expanding Role of PQIs
- Hormonal Contraceptive Initiation Associated With Increased Risk of Depression Postpartum in First-Time Mothers